{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:32:51Z","timestamp":1791516771254,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aohep.2026.102259","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:02:10Z","timestamp":1784534530000},"page":"102259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"31","author":[{"given":"Qingping","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102259_bib0001","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102259_bib0002","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","author":"Guix\u00e9-Muntet","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Fern\u00e1ndez-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0005","first-page":"265","article-title":"Preventing the progression of cirrhosis to decompensation and death","volume":"22","author":"Villanueva","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol\u2013a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102259_bib0007","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0008","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102259_bib0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1478-3231.2011.02579.x","article-title":"Endothelial dysfunction in the regulation of cirrhosis and portal hypertension","volume":"32","author":"Iwakiri","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102259_bib0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102259_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0012","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102259_bib0013","article-title":"Statin therapy and portal pressure reduction in cirrhosis: a systematic review and meta-analysis","volume":"45","author":"Ahmed","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102259_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.aohep.2026.102259_bib0015","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review","volume":"131","author":"D'Amico","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102259_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2026.102259_bib0017","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4067\/s0034-98872017001101463","article-title":"Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation)]","volume":"145","author":"Mendoza","year":"2017","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.aohep.2026.102259_bib0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2026.102259_bib0019","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102259_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0021","doi-asserted-by":"crossref","first-page":"020","DOI":"10.29328\/journal.acgh.1001010","article-title":"Addition of Simvastatin to Carvedilol and Endoscopic Variceal ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class","volume":"3","author":"Jha","year":"2019","journal-title":"Ann Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0022","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s43066-021-00143-2","article-title":"Survival benefits of adding simvastatin to standard therapy for secondary prevention of bleeding esophageal varices in patients with hepatitis C-related liver cirrhosis","volume":"11","author":"Elshazly","year":"2021","journal-title":"Egypt Liver J"},{"key":"10.1016\/j.aohep.2026.102259_bib0023","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to Carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102259_bib0024","article-title":"Simvastatin addition to standard of care improves long-term survival in patients with cirrhosis after variceal bleed: an open label randomized controlled trial","author":"Rana","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102259_bib0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/HEP.0000000000001148","article-title":"Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to \u03b2-blockers: a double-blind, placebo-controlled, randomized trial","volume":"82","author":"Alvarado-Tapias","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102259_bib0026","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102259_bib0027","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0028","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0029","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with Hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102259_bib0030","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102259_bib0031","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0032","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.aohep.2026.102259_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030038","article-title":"Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients","volume":"9","author":"Wan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.aohep.2026.102259_bib0034","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and Rifaximin in decompensated cirrhosis: a randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2026.102259_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102259_bib0036","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s10620-020-06630-7","article-title":"Safety of chronic simvastatin treatment in patients with decompensated cirrhosis: many adverse events but No liver injury","volume":"66","author":"Mu\u00f1oz","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2026.102259_bib0037","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1007\/s10620-023-07970-w","article-title":"Statins in cirrhosis: trial data are in but the jury is still out","volume":"68","author":"Kaplan","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2026.102259_bib0038","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:40:11Z","timestamp":1791366011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1665268126000797"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102259","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102259"}}